ONR-001 / Oniria Therapeutics - LARVOL DELTA

Advancing the preclinical development of ONR-001, a first-in-class TET2 activator for the treatment of cancer (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Preclinical • Oncology • TET2